New hope for right heart failure: drug combo trial launches

NCT ID NCT06570473

First seen Sep 30, 2025 · Last updated May 16, 2026 · Updated 22 times

Summary

This study tests whether adding empagliflozin or ranolazine to standard treatment can improve right heart function in 30 adults with pulmonary hypertension and right heart failure. Participants are randomly assigned to one of the two drugs plus usual care, or usual care alone. The main goal is to see if a larger trial is possible, while also checking heart function, exercise ability, and safety.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RIGHT VENTRICULAR DYSFUNCTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • London Health Sciences Centre - University Hospital

    NOT_YET_RECRUITING

    London, Ontario, N6A 5A5, Canada

  • The Ottawa Hospital

    NOT_YET_RECRUITING

    Ottawa, Ontario, K1Y 4E9, Canada

  • The University of British Columbia

    NOT_YET_RECRUITING

    Vancouver, British Columbia, V5Z 1M9, Canada

  • University of Alberta

    RECRUITING

    Edmonton, Alberta, T6G 2G3, Canada

  • University of Calgary

    NOT_YET_RECRUITING

    Calgary, Alberta, T1Y 6J4, Canada

Conditions

Explore the condition pages connected to this study.